Álvarez-Camino JC, Vázquez-Delgado E, Gay-Escoda C. Use of autologous
conditioned serum (Orthokine®) for the treatment of
the degenerative osteoarthritis of the temporomandibular
joint. Review of the literature. Med Oral Patol Oral
Cir Bucal. 2013 May 1;18 (3):e433-8.
doi:10.4317/medoral.18373
http://dx.doi.org/doi:10.4317/medoral.18373
|
1. Machon V, Hirjak
D, Lukas J. Therapy of the osteoarthritis of the temporomandibular
joint. J Craniomaxillofac Surg. 2011;39:127-30. |
|
|
|
|
|
2. Onder ME, Tüz
HH, Koçyiğit D, Kişnişci
RS. Long-term results of arthrocentesis in
degenerative temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:e1-5. |
|
|
|
|
|
3. Yang KG, Raijmakers NJ, van Arkel ER, Caron JJ, Rijk PC, Willems WJ, et al. Autologous
interleukin-1 receptor antagonist improves function and symptoms in
osteoarthritis when compared to placebo in a prospective randomized
controlled trial. Osteoarthr Cartil. 2008;16:498-505. |
|
|
|
|
|
4. Clegg DO, Reda DJ, Harris CL, Klein MA,
O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin
sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795-808. |
|
|
|
|
|
5. Vernal R, Velásquez E, Gamonal J, Garcia-Sanz JA,
Silva A, Sanz M. Expression of proinflammatory
cytokines in osteoarthritis of the temporomandibular
joint. Arch Oral Biol. 2008;53:910-5. |
|
|
|
|
|
6. Abramson SB, Amin A. Blocking the effects
of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology. 2002;41:972-80. |
|
|
|
|
|
7. Rutgers M, Saris DB, Dhert WJ, Creemers LB. Cytokine profile of autologous
conditioned serum for treatment of osteoarthritis, in vitro effects on
cartilage metabolism and intra-articular levels
after injection. Arthritis Res Ther. 2010;12:R114. |
|
|
|
|
|
8. Frisbie DD, Ghivizzani
SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine
osteoarthritis by in vivo delivery of the equine interleukin-1 receptor
antagonist gene. Gene Ther. 2002;9:12-20. |
|
|
|
|
|
9. Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous
conditioned serum (Orthokine) is an effective
treatment for knee osteoarthritis. Osteoarthritis Cartilage. 2009;17:152-60. |
|
|
|
|
|
10. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The
production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm
Res. 2003;52:404-7. |
|
|
|
|
|
11. Frisbie DD, Kawcak
CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical,
and histologic effects of intra-articular
administration of autologous conditioned serum in
horses with experimentally induced osteoarthritis. Am J Vet Res. 2007;68:290-6. |
|
|
|
|
|
12. Zhang B, Hu J, Man C, Zhu S. Effect of
intra-articular administration of interleukin 1
receptor antagonist on cartilage repair in temporomandibular
joint. J Craniofac Surg. 2011;22:711-4. |
|
|
|
|
|
13. Wright-Carpenter T, Klein P, Schäferhoff
P, Appell HJ, Mir LM, Wehling
P. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen
with muscle strains. Int J Sports Med. 2004;25:588-93. |
|
|
|
|
|
14. Wehling P, Moser C, Frisbie
D, McIlwraith CW, Kawcak CE, Krauspe
R, et al. Autologous conditioned serum in the
treatment of orthopedic diseases: the orthokine
therapy. BioDrugs. 2007;21:323-32. |
|
|
|
|
|
15. Darabos N, Hundric-Haspl
Z, Haspl M, Markotic A, Darabos A, Moser C. Correlation between synovial fluid
and serum IL-1beta levels after ACL surgery-preliminary report. Int Orthop. 2009;33:413-8. |
|